ClinicalTrials.gg
RecruitingNCT06078449Updated Oct 11, 2023

Ultrasound Effect With Hyaluronate Injection on Risk of Fall in Geriatric Women With Knee Osteoarthritis

An interventional study of Therapeutic Ultrasonic and Hyaluronan intra-articular injection in Osteo Arthritis Knee, sponsored by Badr University. Recruiting at 1 site in Egypt. Open to female participants aged 65 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-10-11.

Sponsored by Badr University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 8 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
65 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Osteoarthritis with a site in Egypt — 12 open to participants now, 12 under way, 1 of them phase 3. Osteoarthritis · Egypt.

Planned enrollment
18th of 27
40 · median 60
Started
2023
with 3 others
No phase
23 of 33
10 open now
Primary completion
2024-03
later than 0 of 11 live
Registered
14th of 33
by date
Lead sponsor
2 of 33
Badr University

Among the 33 studies in Osteoarthritis with a site in Egypt, this one is the 18th largest by planned enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2023, is one of 23 with no phase, reaches primary completion later than 0 of the 11 other live ones, and was the 14th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

12 of the 33 studies in Osteoarthritis with a site in Egypt are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 65 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Osteoarthritis with a site in Egypt, or all of them as a file.
02

Study summary

For many years' physiotherapists have been using ultrasound in treatment of knee osteoarthritis especially in geriatrics (people aged above 65 years) for its known therapeutic effect in relieving pain and improving knee function. Hyaluronan is used to treat osteoarthritis of the knee. Such treatments, called viscosupplementation, are administered as a course of injections into the knee joint, and are believed to supplement the viscosity of the joint fluid, thereby lubricating the joint, cushioning the joint, and producing an analgesic effect. Studies reveals the risk for falls increases with additional symptomatic OA lower limb joints and confirms in addition to gender factor; including female sex.

Read the detailed description

It is hypothesized that physical therapy by ultrasound might add some extra benefit on risk of fall when applied after intra-articular hyaluronate of Knee OA in female geriatrics. So, forty female geriatrics with ages ranged from 65 to 75 years, randomly will be selected from Ahmed Maher Teaching Hospital, Kasr el einy hospital, Charity clinic and Outpatient clinic of Badr university, referred to physical therapy by an orthopedic surgeon. All will be diagnosed as chronic OA of one or both knees where conventional therapeutic measures failed. They will be assigned to begin HA intra-articular knee injection by the orthopedic surgeon once weekly for 3 weeks. These patients will be randomly divided into 2 groups equal in number, group (1) the study group, they will receive HA intra-articular injection in addition to 12 sessions of therapeutic ultrasound, while group (2) served as the control group receiving only HA intra-articular knee injection.

03

Conditions studied

  • Osteo Arthritis Knee

Browse trials for

Keywords

  • Risk of fall
  • osteoarthritis
  • hyaluronate
  • geriatric females
04

Who can participate

Ages eligible
65 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients' ages above 65 years.
  • Patients diagnosed as chronic osteoarthritis of more than 5 years.
  • The OA diagnosed as grade (III to V)
  • Patients failed with conventional treatment.
  • All patients followed up with the same orthopedic surgeon, and they took the same type of HA intra-articular injection (HA of High MW 3000 kDa).
  • All patients were medically stable and do not suffer from any other diseases which may affect the trial results.
  • All patients were not treated with analgesics or any medication which may cause misleading results.
  • None of the patients received intra-articular hyaluronic acid injection for 1 year or intra-articular injection within the last 3 months.
  • All patients didn't take or oral glucosamine or chondroitin supplements or stopped these drugs 2-3 months before participating in this study.
  • Every patient signed a consent form.

Exclusion criteria

Exclusion Criteria:

  • Young individuals (their age is below 65 years old).
  • Mild degree of OA (grade I \& II).
  • Patients who had undergone knee arthroscopy, or any knee surgery.
  • Patients with OA secondary to trauma.
  • Patients with metal implants.
  • Patients with CNS dysfunction.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Injection group

    Group (1) the study group, they will receive HA intra-articular injection in addition to 12 sessions of therapeutic ultrasound.

    Device: Therapeutic Ultrasonic · Drug: Hyaluronan intra-articular injection

  • Other
    Ultrasound group

    Group (2) served as the control group, will receive only HA intra-articular knee injection.

    Drug: Hyaluronan intra-articular injection

Interventions

  • DeviceTherapeutic Ultrasonic

    Ultrasound is a therapeutic modality that has been used by physical therapists to achieve therapeutic benefits. It is alternating compression and rarefaction of sound waves with a frequency of \>20,000 cycles/second. Therapeutic ultrasound frequency will be used by 0.7 to 3.3 MHz. Maximum energy absorption in soft tissue will be 2 to 5 cm. Intensity decreases as the waves penetrate deeper. It is applied using a round headed wand or probe that is put in direct contact with the patient's skin. Ultrasound gel must be used on all surfaces of the head as a conducting medium in order to assist in the transmission of the ultrasonic waves \& to reduce friction.

  • DrugHyaluronan intra-articular injection

    The type of Hyaluronan injection that will be used in this study consists of High Molecular Weight Hyaluronic acid (High MW HA 3000 kDa), will be given by the orthopedic surgeon.

06

What researchers measure

Primary outcomes

  1. ROM

    Range of motion by using OB Goniometer "Myrin"

    Time frame: At the beginning of study, we measure range of motion in patients in both groups then after one month to assess progression of range of motion in both groups.

  2. 6 min walk test

    The 6MWT required a 100-ft hallway but no exercise equipment or advanced training for technicians. This test measured the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes.

    Time frame: At the beginning of study, we assess balance by 6 min walk test in patients in both groups then after one month to assess progression in balance in both groups.

  3. Berg balance scale

    The Berg Balance Scale (BBS) is used to objectively determine a patient's ability (or inability) to safely balance during a series of predetermined tasks. It is a 14 item list with each item consisting of a five-point ordinal scale ranging from 0 to 4, with 0 indicating the lowest level of function and 4 the highest level of function and takes approximately 20 minutes to complete. It does not include the assessment of gait.

    Time frame: At the beginning of study, we assess balance by Berg balance scale in patients in both groups then after one month to assess progression in balance in both groups.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2023; primary completion for Mar 2024, 4 months later.

Of 578 non-industry interventional studies with no phase under Osteoarthritis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 4 months is below that.

Counting every sponsor, half of 713 studies reached it within 28 months; a quarter within 11 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2023
First posted
Oct 11, 2023
StartEst.
Nov 11, 2023
Primary completionEst.
Mar 11, 2024
CompletionEst.
Mar 30, 2024
Last update
Oct 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06078449
Lead sponsor
Badr University
Responsible party
Hend Reda Sakr (Lecturer of Physical Therapy for Woman's Health, Badr University) — Principal investigator
First posted
Oct 11, 2023
Start date
Nov 11, 2023 (estimated)
Primary completion
Mar 11, 2024 (estimated)
Completion
Mar 30, 2024 (estimated)
Last update
Oct 11, 2023

Study contacts

Hend R Sakr, PhD
Contact
hend.reda@buc.edu.eg
+201010151300

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion